What is ‘Prussian blue insoluble formulations’?

March 15, 2023

A critical drug, 'prussian blue' insoluble formulations developed on a Defence Research and Development Organisation (DRDO) technology recently received approval from the Drugs Controller General of India (DCGI).

About Prussian blue insoluble formulations:

  • It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies. 
  • It was developed under the Technology Development Fund (TDF).
    The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
  • The formulations are used for the decontamination of Cesium and Thallium.
  • The manufacturing and marketing licenses for the commercial use of the drug have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh, and Skanttr Lifescience, Gujarat, by DCGI.
  • The drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.

What is the Technology Development Fund (TDF)?

  • It has been established to promote self-reliance in defense technology as a part of the 'Make in India' initiative.
  • It is a program of the Ministry of Defence executed by DRDO meeting the requirements of Tri-Services, Defence Production, and DRDO. 
  • It supports the indigenous development of components, products, systems, and technologies by MSMEs and start-ups.
  • Funding:
    • The project cost of up to INR 10 Cr will be considered for funding, subject to a maximum of 90% of the total project cost.
    • The funding will be through the provision of grants to the industry.